Clinical Trials Browser

NIH × Uterine Cervical Neoplasms × Nivolumab × Clear all

NCT02257528 2025-09-08

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 2 Active not recruiting

26 enrolled 12 charts

Uterine Cervical Neoplasms

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Phase 2 Withdrawn

DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms